1. Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population
- Author
-
Prakash Deedwania, M A Bethel, Alice Huntsman-Labed, Robert M. Califf, Peter Diem, Steven M. Haffner, Naomi S. Levitt, and Ole Schmitz
- Subjects
medicine.medical_specialty ,education.field_of_study ,Glucose tolerance test ,biology ,medicine.diagnostic_test ,business.industry ,Endocrinology, Diabetes and Metabolism ,Fatty liver ,Population ,Nateglinide ,medicine.disease ,digestive system diseases ,Impaired glucose tolerance ,Endocrinology ,Alanine transaminase ,Internal medicine ,Internal Medicine ,medicine ,biology.protein ,Biomarker (medicine) ,Metabolic syndrome ,business ,education ,medicine.drug - Abstract
Non-alcoholic fatty liver disease (NAFLD) is associated with features of the metabolic syndrome (MetS) and may be an expression of the syndrome within the liver. Using screening data from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study (n = 42 149), we examined whether alanine aminotransferase (ALT), a biomarker for NAFLD, clustered with features of MetS and whether the clusters differed across global geographic regions.
- Published
- 2009
- Full Text
- View/download PDF